Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation

Molecular Genetics and Metabolism

Volumn 105, Issue 4, 2012, Pages 607-614

  El Hattab, Ayman W ^a   Hsu, Jean W ^b   Emrick, Lisa T ^b,c   Wong, Lee Jun C ^b   Craigen, William J ^b,c   Jahoor, Farook ^b   Scaglia, Fernando ^b,c  

^a UNIVERSITY OF MISSOURI   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Clinical research; Endothelial dysfunction; Mitochondrial diseases; Nitric oxide synthase; Stable isotope; Stroke

Indexed keywords

ARGININE; CITRULLINE; DIMETHYLARGININASE; ISOTOPE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIET SUPPLEMENTATION; FEMALE; HUMAN; MALE; MELAS SYNDROME; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; THERAPY EFFECT;

ADOLESCENT; ADULT; ARGININE; CASE-CONTROL STUDIES; CITRULLINE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; MALE; MELAS SYNDROME; MIDDLE AGED; NITRIC OXIDE; PROGNOSIS; YOUNG ADULT;

EID: 84858700111     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.01.016     Document Type: Article

References (32)

1. Chinnery P.F., Turnbull D.M. Epidemiology and treatment of mitochondrial disorders. Am. J. Med. Genet. 2011, 106:94-101.
2. Wallace D.C. Diseases of the mitochondrial DNA. Annu. Rev. Biochem. 1992, 61:1175-1212.
3. Hirano M., Pavlakis S.G. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J. Child Neurol. 1994, 9:4-13.
4. Scaglia F., Northrop J.L. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) Syndrome. A review of treatment options. CNS Drugs 2006, 20:443-464.
5. Sproule D.M., Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann. N. Y. Acad. Sci. 2008, 1142:133-158.
6. Koga Y., Akita Y., Nishioka J., et al. l-Arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005, 64:710-712.
7. Ohama E., Ohara S., Ikuta F., et al. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta Neuropathol. 1987, 74:226-233.
8. Goto Y., Horai S., Matsuoka T., et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. Neurology 1992, 42:545-550.
9. Naini A., Kaufmann P., Shanske S., et al. Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox". J. Neurol. Sci. 2005, 229:87-193.
10. Green D.J., Maiorana A., O'Driscoll G., Taylor R. Effect of exercise training on endothelium-derived nitric oxide function in humans. J. Physiol. 2004, 561:1-25.
11. Toda N., Okamura T. The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol. Rev. 2003, 55:271-324.
12. Palmer R.M., Rees D.D., Ashton D.S., Moncada S. l-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 1988, 153:1251-1256.
13. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 1993, 329:2002-2012.
14. Wu G., Morris S.M. Arginine metabolism: nitric oxide and beyond. Biochemical 1998, 336:1-17.
15. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action. Pharmacol. Res. 2009, 60:448-460.
16. Vallance P., Leone A., Calver A., et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
17. Surdacki A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J. Cardiovasc. Pharmacol. 1999, 33:652-658.
18. Wang D., Strandgaard S., Iversen J., Wilcox C.S. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2009, 296:195-200.
19. Asagami T., Abbasi F., Stuelinger M., et al. Metformin treatment lowers asymmeteric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2003, 51:843-846.
20. Tarnow L., Hovind P., Teerlink T., Stehouwer C.D., Parving H.H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 2004, 27:765-769.
21. Koga Y., Akita Y., Nishioka J., et al. MELAS and l-arginine therapy. Mitochondrion 2007, 7:133-139.
22. Mori M., Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem. Biophys. Res. Commun. 2000, 3:715-719.
23. Kao C.C., Bandi V., Guntupalli K.K., et al. Arginine, citrulline and nitric oxide metabolism in sepsis. Clin. Sci. (Lond) 2009, 117:23-30.
24. Tsikas D., Boger R.H., Bode-Boger S.M., et al. Quantification of nitrite and nitrate in human urine and plasma as pentafluorobenzyl derivatives by gas chromatography-mass spectrometry using their 15N-labelled analogs. J. Chromatogr. B Biomed. Appl. 1994, 661:185-191.
25. Jahoor F., Badaloo A., Villalpando S., et al. Arginine flux and intravascular nitric oxide synthesis in severe childhood undernutrition. Am. J. Clin. Nutr. 2007, 86:1024-1031.
26. Castillo L., Chapman T.E., Sanchez M., et al. Plasma arginine and citrulline kinetics in adults given adequate and arginine-free diets. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:7749-7753.
27. Villalpando S., Gopal J., Balasubramanyam A., et al. In vivo arginine production and intravascular nitric oxide synthesis in hypotensive sepsis. Am. J. Clin. Nutr. 2006, 84:197-203.
28. Vattemi G., Mechref Y., Marini M., et al. Increased protein nitration in mitochondrial diseases: evidence for vessel wall involvement. Mol. Cell Proteomics 2011, 10. (M110.002964).
29. Parfait B., de Lonlay P., von Kleist-Retzow J.C., et al. The neurogenic weakness, ataxia and retinitis pigmentosa (NARP) syndrome mtDNA mutation (T8993G) triggers muscle ATPase deficiency and hypocitrullinaemia. Eur. J. Pediatr. 1999, 55:55-58.
30. Moinard C., Cynober L. Citrulline: a new player in the control of nitrogen homeostasis. J. Nutr. 2007, 137:1621S-1625S.
31. Harris R.A., Joshi M., Jeoung N.H., Obayashi M. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J. Nutr. 2005, 135:1527S-1530S.
32. Coman D., Yaplito-Lee J., Boneh A. New indications and controversies in arginine therapy. Clin. Nutr. 2008, 27:489-496.